Abzena and Mabqi partner for drug development solution

📊 Healthcare News Analysis: Our editorial team has analyzed recent developments from pharmaceutical-technology.com in the Healthcare sector. This report covers key insights related to medical treatment, surgery, prescription and emerging industry trends that professionals should monitor closely.

The Healthcare landscape is evolving, with recent reports indicating notable changes. Share

Copy Link
Share on X
Share on Linkedin
Share on Facebook

The partnership’s services will utilise Mabqi’s LiteMab for hit selection, screening, and characterisation, alongside Abzena’s GMP manufacturing expertise. Abzena and Mabqi have revealed a partnership integrating antibody discovery capabilities with development and manufacturing services for a drug development solution. Through this integration, the collaboration aims to provide biopharma customers with an end-to-end, streamlined solution that bridges discovery through selection of lead candidates into pre-clinical development and beyond.

Sources indicate that go deeper with GlobalData

Reports LOA and PTSR Model – Izokibep in Panuveitis
Reports LOA and PTSR Model – Izokibep in Posterior Uveitis

Go deeper with GlobalData
The gold standard of business intelligence. Evidence suggests that find out more
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms. Find out more
The partnership also addresses early-stage development challenges by combining accelerated development timelines, scientific and technical support, and streamlined workflows.

Its integrated services will utilise Mabqi’s LiteMab antibody discovery studio for hit selection, screening and characterisation by employing pH-sensitive and universal libraries to identify top lead candidates. The offerings will also leverage Abzena’s expertise in GMP manufacturing, cell line development, developability, and process development. Both organisations support a broad range of modalities, including bioconjugates, bi and multi-specifics, monoclonal antibodies (mAbs) and mAb fragments.

GlobalData Strategic Intelligence US Tariffs are shifting – will you react or anticipate? Don’t let policy changes catch you off guard. Data shows that stay proactive with real-time data and expert analysis.

By GlobalData Learn more about Strategic Intelligence
Abzena chief scientific officer Campbell Bunce stated: “Our partnership with Mabqi brings together two science-rich organisations that are focused on advancing antibody innovation through integration. Data shows that “The combination of our capabilities enables us to significantly accelerate our customers’ discovery programmes from end-to-end by leveraging data to streamline and de-risk earlier on in development, enabling a faster and more successful path to the clinic.”
Mabqi CEO Sylvain Yon said: “Our strategic partnership with Abzena marks a significant milestone in offering an integrated antibody discovery-through-development solution by combining our complementary scientific expertise and advanced capabilities. “Beyond scientific excellence and innovation, what truly sets this collaboration apart is the exceptional human fit between our teams ensuring smooth cooperation, shared dedication to innovation and customer-focused relationship.”
The companies together aim to expedite differentiated therapeutic antibodies development for patients globally.

According to reports that sign up for our daily news round-up! Give your business an edge with our leading industry insights. Sign up
Pharmaceutical Technology Excellence Awards – The Benefits of Entering
Gain the recognition you deserve!

The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Copy Link
Share on X
Share on Linkedin
Share on Facebook

Reports LOA and PTSR Model – Izokibep in Panuveitis
Reports LOA and PTSR Model – Izokibep in Posterior Uveitis

Go deeper with GlobalData
The gold standard of business intelligence. Find out more
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.

These developments reflect broader trends shaping the Healthcare industry as organizations adapt to evolving market conditions.

— Based on reporting from pharmaceutical-technology.com

💡 Key Industry Insights

The focus on preventive care and patient outcomes continues to drive industry transformation.

Specifically regarding surgery, market observers note continuing evolution in service delivery, pricing models, and customer engagement strategies that merit close attention from industry stakeholders.

Market Impact: These developments in medical treatment may significantly influence market dynamics. Industry experts recommend monitoring these trends closely for strategic planning purposes.

Analysis Note: This comprehensive overview synthesizes current market intelligence from pharmaceutical-technology.com regarding surgery and related sectors. Stay informed about ongoing developments in this rapidly evolving landscape.